Drug Pipeline Database & Screener

Over 2000 drug entries from about 500 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Drug pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing 574 companies

Screener

Sort

Company Price Change Market Cap Outstanding Shares Short Ratio Updated

Stage

Any... Phase 1a Phase 1 Phase 1b Phase 1/2 Phase 2a Phase 2 Phase 2b Phase 2/3 Phase 3 NDA Filing sNDA Filing BLA Filing PDUFA PDUFA priority review Approved CRL

Indication

Any... 22q11.2 Deletion Syndrome AADC deficiency Abdominal symptom claims (ASC) Achalasia Achondroplasia Achromatopsia Acid sphingomyelinase deficiency (ASMD) Acinetobacter baumannii infections Acne Acquired thrombotic thrombocytopenic purpura (aTTP) Acromegaly Actinic keratosis Acute bacterial skin and skin structure infections (ABSSSI) Acute Coronary Syndrome Acute hepatic porphyrias Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Acute myocardial infarction (AMI) Acute otitis externa Acute Promyelocytic Leukemia acute pyelonephritis Acute Respiratory Distress Syndrome Acute-on-Chronic Liver Failure (ACLF) Adenosine deaminase severe combined immunodeficiency (ADA-SCID) Adenovirus ADHD Adrenoleukodystrophy (ALD) Adult Growth Hormone Deficiency (AGHD) Age-related macular degeneration (AMD) Agitation Alagille Syndrome (ALGS) Alcohol Use Disorder Alcohol-induced liver decompensation (AILD) Alcoholic Hepatitis Alcoholic steatohepatitis (ASH) Alopecia areata Alpha-1 Antitrypsin deficiency (AATD) Alport Syndrome Alstrom Syndrome Alzheimer’s disease Ammonia Amyloidosis Amyotrophic Lateral Sclerosis (ALS) Anal cancer Anal fissures Anaphylaxis ANCA-associated vasculitis (AAV) Androgenetic alopecia (AGA) Androgenic Alopecia Anemia Angelman syndrome Angina Angiosarcoma Animal related Ankylosing spondylitis Anthrax Arginase I deficiency Asthma Atopic dermatitis Atopic keratoconjunctivitis Atrial fibrillation (AF) ATTR (transthyretin amyloidosis) atypical Hemolytic Uremic Syndrome (aHUS) Autism Autism Spectrum Disorder (ASD) Auto-immune Hemolytic Anemia (AIHA) Autoimmune pulmonary alveolar proteinosis (PAP) autosomal dominant retinitis pigmentosa (adRP) Autosomal Recessive Congenital Ichthyosis Autosomal Recessive Stargardt Disease Axial Spondyloarthritis Axillary hyperhidrosis B-Cell Lymphoma Back pain Bacteremia Bardet-Biedl Syndrome Barth Basal cell carcinoma Batten Disease Behcet's Disease Benign Prostatic Hyperplasia (BPH) Beta-Thalassemia Biliary atresia Biliary Tract Cancer Biosimilar Bipolar depression Bladder cancer Bladder pain syndrome/interstitial cystitis (BPS/IC) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Bleeding Blepharoptosis Blindness Bowel related Brain cancer Brain injury Breast cancer Bronchiectasis Bulimia Bullous Pemphigoid Bunionectomy C. difficile Infection C3 glomerulopathy (C3G) Cachexia Candida Auris Candidemia Carcinoid Syndrome Carcinoma In-Situ (CIS) Cardiomyopathy Cardiovascular disease Cartilage/Knee Catecholamine-resistant hypotension (CRH) CDKL5 disorder Celiac disease Celluite Cervical cancer Cervical dysplasia Cervical dystonia Charcot-Marie-Tooth disease (CMT) Chemotherapy induced nausea and vomiting (CINV) Chemotherapy-induced neutropenia (CIN) Chikungunya vaccine Chikungunya Virus Infection Cholangiocarcinoma Choroideremia Chronic cough Chronic Dysphonia Chronic idiopathic constipation (CIC) Chronic Kidney Disease-Associated Pruritus Chronic Lymphocytic Leukemia (CLL) Chronic myelogenous leukemia Chronic myelomonocytic leukemia (CMML) Chronic obstructive pulmonary disease (COPD) Chronic Prostatitis Chronic spontaneous urticaria Chronic Urticaria Cocaine related Cold agglutinin disease Colon cancer Colorectal cancer Community-acquired bacterial pneumonia (CABP) Complement-dependent Nephropathies (CDN) Complex regional pain syndrome (CRPS) Complicated intra-abdominal infections (cIAI) Complicated urinary tract infections (cUTI) Condyloma Congenital Adrenal Hyperplasia (CAH) Congenital hyperinsulinism Congenital Myasthenic Syndromes (CMS) Conjunctivitis Connective tissue growth factor (CTGF) Constipation Contact lens Contraception Contrast-induced Nephropathy Coronary artery disease (CAD) Coronary microvascular dysfunction (CMD) Cow’s milk protein allergy (CMPA) Crigler-Najjar Critical limb ischemia (CLI) Crohn’s Disease Cushings syndrome Cutaneous fibrosis Cutaneous squamous cell carcinoma Cutaneous T-cell lymphoma (CTCL) Cystic fibrosis Cystinosis Cystinuria Cytomegalovirus (CMV) Danon disease Degenerative cervical myelopathy (DCM) Delayed sleep phase disorder (DSPD) Dementia Dengue Depression Dermal scarring Dermatomyositis Desmoid tumors Developmental and Epileptic Encephalopathies (DEE) Diabetes Diabetic cardiomyopathy (DbCM) Diabetic Foot Ulcers Diabetic macular edema (DME) Diabetic nephropathy Diabetic neuropathy Diabetic Retinopathy Diarrhea Diffuse Intrinsic Pontine Glioma (DIPG) Diffuse Large B-Cell Lymphoma (DLBCL) Dravet Syndrome Dry eye disease Duchenne Muscular Dystrophy Ductal Carcinoma in Situ (DCIS) Dyslipidemia Ebola Eczema Egg Allergy End Stage Renal Disease on Dialysis Endometrial cancer Endometriosis Eosinophilic esophagitis Eosinophilic Gastritis Eosinophilic Granulomatosis with Polyangiitis (EGPA) Epidermolysis Bullosa Epilepsy Epithelioid Sarcoma Epstein-Barr virus (EBV-PTLD) Erectile dysfunction Erythropoietic protoporphyria (EPP) Esophageal cancer Esophagogastric adenocarcinoma Essential hypertension Essential thrombocythemia Essential tremor Ewing sarcoma Exocrine pancreatic insufficiency (EPI) Fabry disease Facioscapulohumeral muscular dystrophy (FSHD) Factor Xa Familial Adenomatous Polyposis (FAP) Familial amyloid polyneuropathy (FAP) Familial amyloidotic cardiomyopathy (FAC) Familial chylomicronemia syndrome (FCS) Familial partial lipodystrophy (FPL) Fanconi Anemia (FA) Fascioliasis Fatty Acid Oxidation Disorders (FAOD) Female Sexual Arousal Disorder (FSAD) Female sexual dysfunction (FSD) Fibrodysplasia ossificans progressiva (FOP) Fibromyalgia Focal segmental glomerulosclerosis (FSGS) Follicular Lymphoma Forehead lines Fragile X syndrome Frailty Friedreich's Ataxia (FA) Friedreich’s ataxia (FA) Frozen Shoulder syndrome Galactosemia Gastric cancer Gastroenteritis Gastroesophageal reflux disease (GERD) Gastrointestinal stromal tumors (GIST) Gastroparesis Gaucher disease Generalized anxiety disorder (GAD) Generalized pustular psoriasis Genital warts Geographic atrophy (GA) Gestational Trophoblastic Neoplasia (GTN) Giant cell arteritis (GCA) Glabellar lines Glaucoma Glioblastoma Multiforme (GBM) Glioma Glomerulopathies Glucocorticoid-induced osteoporosis (GIOP) Glut1 DS Glycogen Storage Disease GM1 gangliosidosis GM2 gangliosidosis GNE Myopathy Gonorrhea Gorlin syndrome Gout Graft versus host disease (GvHD) Granulomatosis with polyangiitis (GPA) Growth hormone deficiency GSD1 Gynecomastia H. pylori Hair-related Head and Neck Cancer Headache Hearing loss Heart failure Heat stroke Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Hemochromatosis Hemophilia Hemophilia A Hemophilia B Hemorrhoids Hemostasis Hepatic Cirrhosis Hepatic encephalopathy Hepatic porphyrias Hepatitis B Hepatitis C (HCV) Hepatitis delta virus (HDV) Hepatocellular carcinoma (HCC) Hepatorenal syndrome (HRS) Hereditary Angioedema (HAE) Hernia Herpes Heterozygous Familial Hypercholesterolemia (HeFH) Hidradenitis Suppurativa High Triglycerides Hip-related HIV Hodgkin lymphoma Homozygous familial hypercholesterolemia (HoFH) Hospital-Acquired Bacterial Pneumonia Hot flashes Human lipomas Human Papilloma Virus (HPV) Huntingtons disease Hutchinson-Gilford Progeria Syndrome (HGPS) Hyperammonemia Hypercholesterolemia Hypereosinophilic syndrome (HES) Hyperkalemia Hyperlipidemias Hyperoxaluria Hyperphosphatemia Hyperprolactinemia Hypertension Hypertriglyceridaemia Hypertriglyceridemia Hypertrophic cardiomyopathy (HCM) Hyperuricemia Hypoactive sexual desire disorder (HSDD) Hypoglycemia Hypogonadism Hypoparathyroidism Hypotension Hypothyroidism Idiopathic Hypersomnia Idiopathic Polypoidal Choroidal Vasculopathy Idiopathic pulmonary fibrosis (IPF) IgA nephropathy IgG4-Related Disease Immune Thrombocytopenic Purpura (ITP) Immune-mediated necrotizing myopathy (IMNM) Incisional complications Indolent Systemic Mastocytosis Infantile spasms (IS) Infections - various Inflammatory bowel disease (IBD) Influenza Inherited Metabolic Disorders (IMD) Insomnia Intermittent claudication (IC) Invasive aspergillosis Invasive candidiasis Irritable bowel syndrome (IBS) IVF Jaundice Jet Lag Disorder Kaposi’s sarcoma Kidney disease Knee arthroplasty Lactose intolerance Lambert-Easton Myasthenic Syndrome (LEMS) Lassa virus Leber's Congenital Amaurosis (LCA) Leber’s hereditary optic neuropathy (LHON) Leiomyosarcoma (LMS) Lennox-Gastaut syndrome Leukemia Leukocyte Adhesion Deficiency-I (LAD-I) Levodopa-Induced Dyskinesia Lipodystrophy Liposarcoma Liver cancer Liver Cirrhosis Liver disease Liver fibrosis Low Cardiac Output Syndrome Lung cancer Lung transplant rejection Lupus Lymphedema Lymphoma Macular Edema Malaria Malignant hyperthermia Malignant pleural disease Mantle cell lymphoma (MCL) Marginal zone lymphoma Medullary thyroid cancer Melanoma Membranous nephropathy Ménière's disease Meningitis Menkes disease Merkel cell carcinoma MERS virus (Middle East Respiratory Syndrome) Mesothelioma Metachromatic leukodystrophy (MLD) Methylmalonic Acidemia (MMA) Microsatellite Instability-High Cancer Microscopic polyangiitis (MPA) Migraine Mitochondrial Myopathy Mmyxoid/round cell liposarcoma (MRCLS) Molluscum Contagiosum Molybdenum cofactor deficiency (MoCD) Motion sickness MPS 7 MPS I MPS II MPS III MPS IIIA MPS IIIB MPS IVA Mucocutaneous candidiasis Multiple myeloma Multiple Osteochondroma (MO) Multiple Sclerosis (MS) Multiple system atrophy (MSA) Myasthenia Gravis (MG) Mycosis Fungoides Mydriasis Myelodysplastic syndromes (MDS) Myelofibrosis Myocardial ischemia Myopia Narcolepsy Nasal polyps Nasopharyngeal cancer Nasopharyngeal carcinoma (NPC) Neuroblastoma Neuroendocrine tumors Neurofibromas Neurogenic Orthostatic Hypotension (nOH) Neuromyelitis Optica Spectrum Disorder (NMOSD) Neuropathic pain Neutropenia Nicotine Addiction Niemann-Pick Disease Non-cystic fibrosis bronchiectasis (non-CF BE) Non-Hodgkin Lymphoma (NHL) Non-infectious uveitis Non-small cell lung cancer (NSCLC) Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Nonproliferative Diabetic Retinopathy Nontuberculous mycobacteria (NTM) Norovirus Obesity Obsessive compulsive disorder (OCD) Obstructive Sleep Apnea (OSA) Ocular Inflammation Oculopharyngeal Muscular Dystrophy Oncology Opioid dependence Opioid overdose Opioid-induced constipation (OIC) Oral Mucositis Ornithine Transcarbamylase (OTC) Deficiency Osteoarthritis Osteoporosis Other Otitis media Ovarian cancer Overactive Bladder (OAB) Pain Painful Lumbosacral Radiculopathy (PLSR) Palmoplantar keratoderma (PPK) Pancreatic cancer Papulopustular Rosacea Parkinson’s disease Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal supraventricular tachycardia (PSVT) Peanut Allergy Pemphigus vulgaris (PV) Pericarditis Peripheral artery disease Peripheral Neuropathic Pain (PNP) Phenylketonuria (PKU) Pheochromocytoma Phosphoglucomutase 1 (PGM1) deficiency Pigmented Villonodular Synovitis (PVNS) PKAN Plantar fasciitis Plaque psoriasis Plasma Plasminogen Deficiency Platelets Pneumonia Polycythemia Vera Pompe Disease Portal Hypertension Post-Bariatric Hypoglycemia (PBH) Post-herpetic neuralgia (PHN) Post-transplant lymphoproliferative disorder Post-traumatic stress disorder (PTSD) Posterior Uveitis Postpartum depression (PPD) Prader-Willi Syndrome (PWS) Pre-term labor Preeclampsia Presbyopia Primary axillary hyperhidrosis Primary biliary cholangitis (PBC) Primary hyperoxaluria (PH) Primary Immune Deficiency Disease (PIDD) Primary immunodeficiency (PI) Primary ovarian insufficiency (POI) Primary palmar hyperhidrosis Primary sclerosing cholangitis (PSC) Progeria Progressive familial intrahepatic cholestasis (PFIC) Progressive keratoconus Progressive supranuclear palsy (PSP) Proliferative vitreoretinopathy (PVR) Prophylaxis Prostate cancer Proteus Syndrome Prurigo nodularis Pruritus Pseudomonas aeruginosa Psoriasis Psoriatic arthritis Psychosis Pulmonary arterial hypertension (PAH) Pulmonary Hypertension Pulmonary sarcoidosis Pyoderma Gangraenosum (PG) Pyoderma Gangrenosum Pyruvate kinase deficiency Rare Bile Acid Synthesis Disorders Renal cancer Renal cell cancer (RCC) Respiratory syncytial virus (RSV) Respiratory Tract Infections Retinal diseases Rett syndrome Rheumatoid Arthritis Richter's Transformation Rosacea RPE65-Deficiency S. aureus Sanfilippo syndrome Sarcomas Schizophrenia Sciatica Scleroderma Seborrheic keratosis (SK) Secondary hyperparathyroidism (SHPT) Secondary hypogonadism Seizures Severe aplastic anemia (SAA) Severe burns Severe Congenital Neutropenia (SCN) Sexual health (female) Sexual health (male) Sezary syndrome Shingles Short bowel syndrome Sialorrhea Sickle disease Sinus related Sinusitis Sjögren-Larsson Syndrome (SLS) Small cell lung cancer (SCLC) Small Fibre Neuropathy Small lymphocytic lymphoma (SLL) Smallpox Smith-Magenis Syndrome Smoking cessation Social Anxiety Disorder (SAD) Soild tumors Solid tumors Spasticity Spinal muscular atrophy (SMA) Spinal muscular atrophy (SMA) Type 1 Spinal muscular atrophy (SMA) Type 2 Spinal muscular atrophy (SMA) Type 3 Spinal-related Spinocerebellar Ataxia sporadic Inclusion Body Myositis (sIBM) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Squamous cell lung cancer SRSE Staphylococcus aureus Status Epilepticus Stress related Stress urinary incontinence (SUI) Stroke Systemic mastocytosis (SM) Systemic Sclerosis T-cell lymphoma Tardive dyskinesia Testosterone related Thrombocytopenia Thrombotic microangiopathy (TMA) Thyroid cancer Thyroid Eye Disease (TED) Tinnitus Tourette syndrome Transfusion-dependent thalassemia (TDT) Transplant Transthyretin cardiomyopathy Trigeminal Neuralgia Tuberous Sclerosis Complex Tumor-induced osteomalacia (TIO) Type 1 diabetes Type 2 diabetes Ulcerative Colitis Urea Cycle Disorder Urinary tract infections Urothelial cancer Usher Syndrome Uterine Fibroids Vascular Ehlers-Danlos Syndrome Vasculitis Vasomotor symptoms (VMS) Veno-occlusive Disease (VOD) Venous Leg Ulcers Venous Thromboembolism (VTE) Vertigo Vitiligo Vulvovaginal candidiasis (VVC) Waldenström’s macroglobulinemia Walnut Allergy Warm autoimmune hemolytic anemia (WAIHA) Warts Wet age-related macular degeneration (AMD) WHIM syndrome Wilson disease Wiskott-Aldrich Syndrome (WAS) Women's health (pain/contraception) Wounds Wrinkles X-linked chronic granulomatous disease (X-CGD) X-Linked Hypophosphatemia (XLH) X-Linked Myotubular Myopathy X-linked Retinitis Pigmentosa (XLRP) X-linked retinoschisis (XLRS) X-linked Severe Combined Immunodeficiency (XSCID) Xerostomia Zika

Market Cap

Any Mega ($200bln and more) Large ($10bln to $200bln) Mid ($2bln to $10bln) Small ($300mln to $2bln) Micro ($50mln to $300mln) Nano (under $50mln) +Large (over $10bln) +Mid (over $2bln) +Small (over $300mln) +Micro (over $50mln) -Large (under $200bln) -Mid (under $10bln) -Small (under $2bln) -Micro (under $300mln)

Price

Any Under $1 Under $2 Under $3 Under $4 Under $5 Under $7 Under $10 Under $15 Under $20 Under $30 Under $40 Under $50 Over $1 Over $2 Over $3 Over $4 Over $5 Over $7 Over $10 Over $15 Over $20 Over $30 Over $40 Over $50 Over $60 Over $70 Over $80 Over $90 Over $100 $1 to $5 $1 to $10 $1 to $20 $5 to $10 $5 to $20 $5 to $50 $10 to $20 $10 to $50 $20 to $50 $50 to $100

Short ratio

Any Low (<5 days) High (>20 days) Under 5 days Under 10 days Under 15 days Under 20 days Under 25 days Under 30 days Over 5 days Over 10 days Over 15 days Over 20 days Over 25 days Over 30 days

Relative Volume

Any Over 10 Over 5 Over 3 Over 2 Over 1.5 Over 1 Over 0.75 Over 0.5 Over 0.25 Under 2 Under 1.5 Under 1 Under 0.75 Under 0.5 Under 0.25 Under 0.1

Price to book

Any Low (<3) High (>50) Under 1 Under 2 Under 3 Under 4 Under 5 Under 6 Under 7 Under 8 Under 9 Under 10 Over 1 Over 2 Over 3 Over 4 Over 5 Over 6 Over 7 Over 8 Over 9 Over 10 Over 20 Over 30 Over 40 Over 50

Apply Filters Reset Filters

Company

Price

Change

No of Shares

Market Cap

Short Ratio

Volume

Avg Daily Volume

Relative Volume

Price to Book

Open

Prev Close

EST EPCD

Updated

ABBV AbbVie Inc.

$71.62

+0.35  +0.49%

1.5 billion

$105.9 billion

6.03

941.4 thousand

9.2 million

0.1

-$12.37

$71.40

$71.27

09/19/2019

Tap to view 41 drug drugs

Drug	Indication	Stage	News
Risankizumab	Ulcerative colitis	Phase 3	Phase 3 trial to be initiated 1H 2018.
Depatuxizumab mafodotin ABT-414	Glioblastoma (rGBM)	Phase 3	Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib	Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)	Phase 3	Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib	Relapsed or refractory MCL mantle cell lymphoma	Approved	Approved November 13, 2013.
Imbruvica	Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy	Approved	Approved February 12, 2014.
Imbruvica	Deletion 17p	Approved	Approved July 19, 2014.
VIEKIRA PAK	HCV - genotype 1	Approved	Approved December 19, 2014.
IMBRUVICA	Waldenström’s Macroglobulinemia	Approved	Approved January 29, 2015 - PCYC
ABBV-8E12	Progressive supranuclear palsy (PSP)	Phase 2	Phase 2 initiation announced January 25, 2017.
ABBV-8E12	Alzheimer's disease	Phase 2	Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO)	Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)	Approved	Approval announced June 11, 2018.
Venetoclax - CANOVA	Relapsed or refractory multiple myeloma	Phase 3	Phase 3 data due in 2021.
Venclexta	First-line Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial planned.
Venclexta	Follicular lymphoma (FL)	Phase 3	Phase 3 trial planned.
Risankizumab	Crohn’s Disease	Phase 3	Phase 3 trial to commence 2H 2017.
Risankizumab	Psoriasis	Approved	FDA approval announced April 23, 2019.
Imbruvica	Second-line Chronic graft-versus-host disease (GVHD)	Approved	Approval announced August 2, 2017.
ABT-494	Psoriatic Arthritis	Phase 3	Phase 3 trial to commenced 2017.
Risankizumab	Psoriatic Arthritis	Phase 2b	Phase 3 trial planned for 2018.
ABT-494	Crohn’s Disease	Phase 3	Phase 3 trial initiated late 2017.
Rova-T (TRINITY)	Third-line Small Cell Lung Cancer	Phase 2	Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
ABT-494	Atopic Dermatitis	Phase 3	Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
Imbruvica	Marginal zone lymphoma	Approved	sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P)	Hepatitis C virus (HCV)	Approved	Approval announced August 3, 2017.
Elagolix	Uterine Fibroids	NDA Filing	NDA filing announced August 5, 2019.
Elagolix	Endometriosis	Approved	FDA approval announced July 24, 2018.
ABT-494 upadacitinib	Rheumatoid arthritis	Approved	FDA Approval announced August 16, 2019.
Rova-T (TAHOE)	Second-line Small Cell Lung Cancer	Phase 3	Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU)	First-line Small Cell Lung Cancer	Phase 3	Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE	Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)	Approved	FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib)	Waldenström’s Macroglobulinemia	Approved	FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)	Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta	First line unfit AML	Approved	FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE	Ulcerative colitis	Phase 2/3	Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab	Chronic Lymphocytic Leukemia	Phase 3	FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica)	Pancreatic cancer	Phase 3	Phase 3 primary endpoint not met (PFS/OS).
Venclexta plus Gazyva	Chronic lymphocytic leukemia (CLL)	Phase 3	Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta MIRROS	Acute myeloid leukemia (AML)	Phase 3	Phase 3 data due 2H 2019.
Venclexta BELLINI	Multiple myeloma	Phase 3	Phase 3 primary endpoint met.
Venetoclax and obinutuzumab	Chronic lymphocytic leukemia	sNDA Filing	sNDA filing announced June 4, 2019.
Veliparib	Ovarian cancer	Phase 3	Phase 3 presentation at ESMO 28 September 2019, 5:08pm.

ABEO Abeona Therapeutics Inc.

$3.45

+0.25  +7.87%

49.3 million

$170.2 million

763.6 thousand

1.2 million

0.63

$1.59

$3.19

$3.20

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
ABO-101	Sanfilippo syndrome type B (MPS IIIB)	Phase 1/2	Phase 1/2 interim data due 2H 2019.
EB-101	Recessive dystrophic epidermolysis bullosa (RDEB)	Phase 1/2	Phase 3 trial to be initiated 4Q 2019.
ABO-102	Sanfilippo syndrome type A (MPS IIIA)	Phase 1/2	Phase 1/2 meeting with FDA 2H 2019 to discuss next steps.
ABO-202	CLN1 disease (Infantile Batten disease)	Phase 1/2	Phase 1/2 trial planned. Timing to be announced later in 2019.

ABIO ARCA biopharma Inc.

$5.68

-0.11  -1.90%

1.5 million

$8.3 million

28.2 thousand

99.9 thousand

0.28

$0.00

$5.77

$5.79

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Gencaro	Chronic Heart Failure	Phase 3	Phase 3 trial to be initiated 1Q 2020 subject to financing. Interim data 4Q 2021; top-line data: 4Q 2022.

ABUS Arbutus Biopharma Corporation

$1.66

+0.06  +3.75%

56.9 million

$94.4 million

16.6 thousand

199.4 thousand

0.08

$2.86

$1.61

$1.60

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ARB-1467, tenofovir, and pegylated interferon	Hepatitis B (HBV)	Phase 2	Phase 2 trial ongoing but no plans to continue further development.
ARB-1467	Hepatitis B (HBV)	Phase 2	Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
AB-452	Hepatitis B	Phase 1	Phase 1 trial initiation delayed - noted October 9, 2018. Decision regarding clinical development due early 2020.
AB-506	Hepatitis B (HBV)	Phase 1	Phase 1 final data due 1H 2020.
AB-729	Hepatitis B (HBV)	Phase 1	Phase 1a/b data due 1Q 2020.

ACAD ACADIA Pharmaceuticals Inc.

$40.88

-1.28  -3.04%

144.5 million

$5.9 billion

419 thousand

2.3 million

0.19

$15.20

$41.98

$42.16

09/19/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Pimavanserin - CLARITY-2	Adjunctive Treatment in Patients With Major Depressive Disorder	Phase 3	Phase 3 trial initiation announced April 25, 2019.
Pimavanserin - Advance	Adjunctive treatment in patients with negative symptoms of schizophrenia	Phase 2	Phase 2 data due year-end 2019.
Pimavanserin - Enhance	Adjunctive treatment of schizophrenia	Phase 3	Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - SERENE	Alzheimer’s disease agitation	Phase 2	Announced October 4, 2017 that trial will be discontinued.
Pimavanserin	Parkinson’s disease psychosis (PDP)	Approved	Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony	Alzheimer’s disease psychosis	Phase 3	Phase 3 trial stopped early after meeting primary endpoint - September 9, 2019.
Trofinetide	Rett Syndrome	Phase 3	Phase 3 trial to be initiated 4Q 2019.

ACER Acer Therapeutics Inc.

$3.52

+0.1  +2.92%

10.1 million

$35.5 million

26.1 thousand

163.7 thousand

0.16

$1.29

$3.47

$3.42

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
EDSIVO	Vascular Ehlers-Danlos Syndrome	CRL	CRL issued June 25, 2019.
Tovaxin (Tcelna)	Secondary Progressive MS (SPMS)	Phase 2b	Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001	Urea cycle disorder (UCD)	Phase 2	Pivotal bridging trial to be initiated 4Q 2019 with NDA filing mid-2020.
Osanetant	induced Vasomotor Symptoms (iVMS)	Phase 1/2	Phase 1/2 trial to be initiated mid-2020.

ACHN Achillion Pharmaceuticals Inc.

$3.80

-0.01  -0.26%

139.7 million

$530.8 million

121.4 thousand

1.7 million

0.07

$2.29

$3.80

$3.81

09/19/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	End of Phase 2 meeting 4Q 2019.
JNJ-4178	Hepatitis C (HCV)	Phase 2a	Janssen noted September 11, 2017 that no further development planned.
Danicopan (ACH-4471)	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 2	Phase 2 full data due 4Q 2019.
JNJ-4178 - OMEGA-1	Hepatitis C (HCV)	Phase 2b	Janssen noted September 11, 2017 that no further development planned.
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	End of Phase 2 meeting 4Q 2019.
ACH-5228	Healthy volunteers	Phase 1	Phase 2 trial planned with Phase 3 trials to potentially commence in early 2020.

ACHV Achieve Life Sciences Inc.

$2.16

  +0.05%

8.1 million

$17.5 million

12.6 thousand

110.8 thousand

0.11

$1.52

$2.12

$2.16

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Cytisine	Smoking cessation	Phase 2b	Phase 2b data met primary endpoint in 3/4 arms - June 11, 2019.

ACIU AC Immune SA

$5.34

+0.14  +2.69%

67.6 million

$360.8 million

8.6 thousand

115.9 thousand

0.07

$1.30

$5.24

$5.20

09/19/2019

Tap to view 9 drug drugs

Drug	Indication	Stage	News
Crenezumab - CREAD 2	Alzheimer’s disease	Phase 3	Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
RG6100 (Anti-Tau RO7105705)	Alzheimer’s disease	Phase 2	Phase 2 data due 3Q 2020.
ACI-24 (anti-Abeta vaccine)	Alzheimer's disease-like characteristics in individuals with Down syndrome	Phase 1/2	Phase 1/2 interim data released July 2019.
Crenezumab - CREAD 1	Alzheimer’s disease	Phase 3	Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
ACI-24	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced August 20, 2018.
MTAU9937A	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced February 20, 2019.
ACI-35	Alzheimer’s disease	Phase 1b	Phase 2 trial planned for 1H 2019.
ACI-3024	Alzheimer’s disease	Phase 1	Phase 1 trial initiation announced July 17, 2019.
ACI-35.030	Alzheimer’s Disease	Phase 1/2	Phase 1b/2 trial initiation announced August 1, 2019.

ACOR Acorda Therapeutics Inc.

$3.49

-0.06  -1.69%

48.1 million

$167.9 million

190.8 thousand

1.7 million

0.11

$0.31

$3.56

$3.55

09/19/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Ampyra	Improve walking in patients with multiple sclerosis		Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
CVT-427	Migraine	Phase 1	Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Tozadenant	Parkinson’s disease (PD)	Phase 3	Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine	Post stroke deficits	Phase 3	Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301)	OFF episodes of Parkinson’s disease (PD)	Approved	FDA Approval announced December 22, 2018.
BTT1023	Primary Sclerosing Cholangitis	Phase 2	Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.

ACRS Aclaris Therapeutics Inc.

$1.46

-0.17  -10.43%

41.4 million

$60.4 million

984.5 thousand

1.8 million

0.54

$0.44

$1.63

$1.63

09/19/2019

Tap to view 8 drug drugs

Drug	Indication	Stage	News
ATI-502 (ATI-50002-AA-201) - dose ranging	Alopecia areata	Phase 2	Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical)	Vitiligo	Phase 2	Development to be discontinued - noted August 8, 2019.
ATI-501 (AUAT-201 Oral)	Alopecia areata	Phase 2	Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ESKATA (hydrogen peroxide)	Seborrheic keratosis (SK)	Approved	Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2	Common warts (verruca vulgaris)	Phase 3	Phase 3 data met all endpoints - September 16, 2019.
ATI-502	Androgenetic alopecia (AGA) - Hair loss	Phase 2	Partner required to further development.
ATI-502 (AD-201 Topical)	Atopic dermatitis (AD)	Phase 2	Phase 2 trial completed.
ATI-450	Rheumatoid arthritis (RA)	Phase 1/2	Phase 1/2 has commenced dosing - August 8, 2019.

ACRX AcelRx Pharmaceuticals Inc.

$2.64

-0.01  -0.38%

79.4 million

$209.7 million

78.1 thousand

970.2 thousand

0.08

-$11.48

$2.66

$2.65

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ARX-04 (SAP302)	Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury	Phase 3	Phase 3 data released August 15 2016
DSUVIA (ARX-04)	Moderate-to-severe acute pain following a surgical procedure	Approved	FDA Approval announced November 2, 2018.
Zalviso	Post-operative pain following open abdominal surgery and hip or knee replacement surgery	Phase 3	CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.

ACST Acasti Pharma Inc.

$2.19

+0.07  +3.30%

85.2 million

$185.8 million

103.9 thousand

2.4 million

0.04

$73.00

$2.12

$2.12

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
CaPre (TRILOGY 1 and 2)	Hypertriglyceridemia	Phase 3	Phase 3 top-line data due in December 2019 (1) and January 2020 (2).

ADAP Adaptimmune Therapeutics plc

$1.71

-0.04  -2.29%

105.1 million

$179.8 million

60.6 thousand

319.7 thousand

0.19

$0.96

$1.78

$1.75

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
MAGE-A4 (ADP-A2M4)	Soild tumors	Phase 1	Phase 1 update due 2H 2019.
AFP (ADP-A2AFP)	Hepatocellular carcinoma	Phase 1	Phase 1 update due 1H 2020.
MAGE-A10 (ADP-A2M10)	Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Phase 1 further data due 2H 2019.
MAGE-A4 (SPEARHEAD‑1)	Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)	Phase 2	Phase 2 interim futility data due 1H 2020.
MAGE-A4 (ADP-A2M4CD8 - SURPASS)	Soild tumors	Phase 1	Phase 1 safety and response data due 1H 2020.

ADIL Adial Pharmaceuticals Inc

$1.47

-0.02  -1.34%

10.2 million

$15.1 million

6.2 thousand

39.7 thousand

0.16

$1.50

$1.50

$1.49

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AD04	Alcohol use disorder	Phase 3	Phase 3 data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023.

ADMA ADMA Biologics Inc

$5.29

  +0.00%

59.3 million

$313.8 million

87.1 thousand

668.4 thousand

0.13

$6.70

$5.31

$5.29

09/19/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
RI-002	Primary Immune Deficiency Diseases	Approved	FDA Approval announced April 1, 2019.
BIVIGAM	Primary humoral immunodeficiency	CRL	Response to Complete Response Letter submitted January 7, 2019.

ADMP Adamis Pharmaceuticals Corporation

$0.76

+0.01  +0.78%

61.4 million

$46.4 million

73.2 thousand

718.4 thousand

0.1

$1.37

$0.76

$0.75

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Epinephrine Pre-filled Syringe (PFS)	Emergency treatment of anaphylaxis.	Approved	CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000	Asthma/COPD	Phase 2	Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose	Anaphylaxis	Approved	FDA Approval announced September 27, 2018.
Higher Dose Naloxone Injection	Opioid overdose	PDUFA	PDUFA date October 31, 2019.
APC-8000 (sublingual tadalafil)	Erectile dysfunction	NDA Filing	Refusal to file letter received February 26, 2019.

ADMS Adamas Pharmaceuticals Inc.

$6.89

+0.25  +3.77%

27.8 million

$191.3 million

419.1 thousand

400.1 thousand

1.05

$4.47

$6.65

$6.64

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ADS-4101	Partial onset seizures in patents with epilepsy	Phase 1b	Further development deferred - noted May 9, 2019.
GOCOVRI (amantadine)	Multiple sclerosis (MS)	Phase 3	Phase 3 data due 4Q 2019.
Namzaric	Moderate to severe dementia of the Alzheimer's type.	Approved	Approved December, 24 2014.
ADS-5102	Levodopa-Induced Dyskinesia	Approved	Approval announced August 24, 2017.
GOCOVRI (amantadine)	Dyskinesia patients with Parkinson's disease	Phase 3	Phase 3 open-label data released April 19, 2018.

ADRO Aduro Biotech Inc.

$1.22

-0.03  -2.40%

80.1 million

$97.8 million

106.9 thousand

365.9 thousand

0.29

$0.97

$1.25

$1.25

09/19/2019

Tap to view 11 drug drugs

Drug	Indication	Stage	News
ADU-S100	Solid tumors or lymphomas	Phase 1b	Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
CRS-207 and GVAX Pancreas - ECLIPSE trial	Pancreatic cancer	Phase 2b	Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial	Pancreatic cancer	Phase 2b	Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with pembrolizumab	Mesothelioma - cancer	Phase 2	Noted December 12, 2017 that development to be discontinued.
pLADD	Colorectal Cancer	Phase 1	Phase 1 ongoing.
pLADD	Colorectal Cancer	Phase 1	Phase 1 ongoing.
ADU-214 with Nivolumab	Non-Small Cell Lung Cancer	Phase 1/2	Phase 1b initiation announced June 7, 2018.
ADU-S100 and Spartalizumab	Solid tumors or lymphomas	Phase 1b	Phase 1 final data due 2020.
ADU-S100 and ipilimumab	Melanoma	Phase 1	Phase 1 commencement of dosing announced February 11, 2019.
BION-1301	IgA Nephropathy	Phase 1	Phase 1 initial data in healthy volunteers expected in 1H 2020 and IgAN patients in 2H 2020.
ADU-S100 and pembrolizumab	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Phase 1/2	Phase 1b/2 initiation of dosing announced September 4, 2019 with initial data due 2020.

ADVM Adverum Biotechnologies Inc.

$6.23

+0.04  +0.65%

64.5 million

$401.6 million

274.8 thousand

2 million

0.14

$2.26

$6.17

$6.19

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ADVM-043	Alpha-1 Antitrypsin (A1AT) Deficiency	Phase 1/2	Development to be discontinued - noted November 1, 2018.
AVA-101	Wet age-related macular degeneration (Wet-AMD)	Phase 2a	Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022	Wet age-related macular degeneration (Wet-AMD)	Phase 1	Phase 1 data from first cohort presented September 12, 2019. Range change in BCVA -9.1 to +5.1 letters.

ADXS Advaxis Inc.

$0.32

-0.04  -10.68%

24.7 million

$7.8 million

12.9 million

1.4 million

9.09

$0.16

$0.37

$0.36

09/19/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Axalimogene filolisbac + durvalumab	Recurrent or refractory HPV-associated cervical cancer and head & neck cancer	Phase 1/2	Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046	Castrate-resistant prostate cancer	Phase 1/2	Phase 1 monotherapy, overall survival was 8.5 months, combo with Keytruda 23 months.
Axalimogene filolisbac - AIM2CERV Trial	High-risk, locally advanced cervical cancer	Phase 3	Phase 3 trial closed - noted June 27, 2019.
ADXS-HER2	HER2-driven malignancies - cancer	Phase 1b	Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac	Anal cancer (FAWCETT)	Phase 2	Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO	Non-small cell lung cancer (NSCLC)	Phase 1	Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-HOT 503	Non-small cell lung cancer (NSCLC)	Phase 1/2	Phase 1/2 preliminary data due 2H 2019.

AERI Aerie Pharmaceuticals Inc.

$22.65

+1.01  +4.67%

45.9 million

$1 billion

229.5 thousand

1.1 million

0.2

$6.68

$21.49

$21.64

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Roclatan	Glaucoma	Approved	FDA Approval announced March 12, 2019.
Rhopressa	Glaucoma	Approved	PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503	Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)	Phase 1/2	Phase 1/2 trial initiation announced August 20, 2019.
AR-1105	Macular edema due to RVO (retinal vein occlusion)	Phase 2	Phase 2 trial initiated March 2019.
Roclatan - Mercury 3	Open Angle Glaucoma	Phase 3	Phase 3 top-line data due 1H 2020.

AEZS Aeterna Zentaris Inc.

$1.74

+0.11  +6.43%

16.4 million

$28.9 million

13.2 thousand

88.9 thousand

0.15

-$9.67

$1.64

$1.63

09/19/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Macimorelin Acetate - Macrilen	Adult Growth Deficiency	Approved	CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex	Endometrial cancer	Phase 3	Phase 3 trial did not meet primary endpoint - May 1, 2017.

AFMD Affimed N.V.

$3.70

+0.05  +1.37%

62.4 million

$231 million

146.4 thousand

571.3 thousand

0.26

$6.27

$3.68

$3.65

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AFM13 with Keytruda	Hodgkin Lymphoma - Cancer	Phase 1b	Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13	Hodgkin Lymphoma - Cancer	Phase 2	Phase 2a ongoing.
AFM13	CD30-positive peripheral T cell lymphoma (PTCL)	Phase 1/2	Phase 2 interim efficacy data due mid-2020. Top-line data due 2021.
AFM11	Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)	Phase 1	Phase 1 program terminated - noted May 22, 2019.

AGEN Agenus Inc.

$3.00

+0.03  +1.01%

137.3 million

$411.9 million

193.1 thousand

863.2 thousand

0.22

-$2.61

$2.99

$2.97

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AGEN2034 and AGEN1884	Solid tumors	Phase 1/2	Phase 1/2 data due 2019.
AGEN1884 (anti-CTLA-4)	Solid cancers	Phase 1	Phase 1 data due 2019.
Shingrix	Shingles	Approved	Approval announced October 20, 2017.
AGEN2034 (anti-PD-1)	Cervical cancer	Phase 1/2	Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN1181 - 2nd gen CTLA	Advanced cancer	Phase 1	Phase 1 data due 2019.

AGIO Agios Pharmaceuticals Inc.

$36.58

+0.08  +0.22%

58.8 million

$2.1 billion

43.6 thousand

571.2 thousand

0.08

$4.03

$36.56

$36.50

09/19/2019

Tap to view 16 drug drugs

Drug	Indication	Stage	News
AG-348 - Mitapivat	Thalassemia	Phase 2	Phase 2 data due 2H 2019.
Ivosidenib	IDH1m Relapsed/Refractory AML - cancer	Approved	FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE)	Pyruvate kinase deficiency	Phase 3	Phase 3 enrolment to be completed 2019.
AG-120 and VIDAZA - AGILE	Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer	Phase 3	Phase 3 enrolment to be completed 2020.
Enasidenib (AG-221) - IDHENTIFY	Refractory Acute myeloid leukemia (AML) - cancer	Phase 3	Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221	Advanced hematologic malignancies with an IDH2 mutation	Approved	Approval announced August 1, 2017.
AG-120 Ivosidenib	IDH1 mutant positive cholangiocarcinoma - cancer	Phase 3	Phase 3 data released May 15, 2019 met primary endpoint. Data to be presented at ESMO September 30, 2019, 4:30pm CEST.
AG-120 Ivosidenib	R/R Acute Myeloid Leukemia (AML)	Phase 1	Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA	Frontline AML with IDH1 or IDH2 mutation	Phase 1/2	Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Ivosidenib or enasidenib	Frontline AML with IDH1 or IDH2 mutation	Phase 1	Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
AG-270	Solid tumors	Phase 1	Phase 1 data to be presented at AACR-NCI-EORTC International Conference October 26-30, 2019
Vorasidenib (AG-881)	Glioma	Phase 3	Phase 3 trial to be initiated YE 2019.
Ivosidenib	Frontline AML with IDH1 mutation	Approved	FDA Approval announced May 2, 2019.
Ivosidenib and Vorasidenib (AG-881)	IDHm low-grade glioma	Phase 1	Phase 1 data presented at ASCO June 3, 2019, 2:15pm.
Ivosidenib	IDH1 mutant newly diagnosed AML ineligible for standard therapies	Phase 1	Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib and azacitidine ( Vidaza)	Newly diagnosed AML with an IDH1 mutation	Phase 1	Phase 1 updated data at ASCO June 3, 2019. 61% CR rate.

AGLE Aeglea BioTherapeutics Inc.

$8.75

+0.08  +0.92%

28.9 million

$252.7 million

2.3 thousand

101.2 thousand

0.02

$2.54

$8.69

$8.67

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AEB1102	Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)	Phase 1	Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102)	Arginase I deficiency	Phase 3	Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021.
AEB1102	Solid tumors	Phase 1	Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102)	Solid tumors	Phase 1	Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA	Small cell lung cancer (SCLC)	Phase 2	Phase 1/2 top-line data due 1H 2020.

AGN Allergan plc

$166.03

+0.03  +0.02%

328.1 million

$54.5 billion

2.28

304.4 thousand

4 million

0.08

$0.91

$166.05

$166.00

09/19/2019

Tap to view 32 drug drugs

Drug	Indication	Stage	News
Botox	Forehead lines	Approved	Approval (third indication) announced October 3, 2017.
RTGel in combination with BOTOX	Overactive Bladder (OAB)	Phase 2	Phase 2 trial to be completed 2H 2019.
JUVÉDERM VOLLURE	Correction of moderate to severe facial wrinkles and folds	Approved	Approval announced March 20, 2017.
Brazikumab	Crohn's disease	Phase 3	Phase 3 ongoing.
Botox	Depression	Phase 2	Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
RORγt agonist	Psoriasis	Phase 2b	Phase 2b trial ongoing.
Cariprazine	Maintenance Treatment of Schizophrenia	Approved	Approval announced November 13, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	Phase 3	Phase 3 data released January 24, 2019 - primary endpoint met in rheumatoid arthritis trial. Non-Hodgkin’s lymphoma data also met primary endpoint showing clinical equivalence - August 22, 2019.
ATOGEPANT	Chronic migraine	Phase 3	Phase 3 data due in 2020.
RAPASTINEL	Major depressive disorder (MDD)	Phase 3	Phase 3 trials did not meet primary endpoints - March 6, 2019.
RELAMORELIN	Diabetic Gastroparesis	Phase 3	Phase 3 top-line data due 2020.
ESMYA (ulipristal acetate)	Uterine Fibroids	CRL	CRL issued August 21, 2018.
ABICIPAR	Diabetic macular edema (DME)	Phase 3	Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC)	Nonalcoholic steatohepatitis (NASH)	Phase 3	Phase 3 data due 2020.
ABICIPAR	Age-related macular degeneration (AMD)	PDUFA priority review	BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI)	Approved	sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0%	Facial Erythema (Redness) Associated with Rosacea	Approved	Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults	Chronic idiopathic constipation (CIC)	Approved	sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	Approved	Approved September 14, 2017.
Sarecycline	Severe acne vulgaris	Approved	FDA Approval announced October 2, 2018.
Cariprazine	Bipolar I Depression	PDUFA	FDA Approval announced May 28, 2019.
UBROGEPANT	Migraine	PDUFA	NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
Brazikumab	Ulcerative colitis	Phase 2/3	Phase 2/3 trial ongoing.
Brimo DDS	Geographic atrophy	Phase 3	Phase 3 trial to be initiated 2H 2018.
Bimatoprost	Open-angle glaucoma or ocular hypertension	PDUFA	PDUFA date 1H 2020. No exact date announced. Estimate May 15, 2020.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI) - pediatric	Approved	FDA Approval announced March 18, 2019.
Botox	Lower limb spasticity	PDUFA	PDUFA date 4Q 2019.
Botox	Upper limb spasticity	Approved	FDA Approval announced June 21, 2019.
AGN-241751	Major Depressive Disorder (MDD)	Phase 2	Phase 2 top-line data due 2H 2019.
Presbysol	Presbyopia	Phase 3	Phase 3 top-line data due 2020.
RAPASTINEL	Depression	Phase 2	Phase 2 monotherapy interim analysis 2H 2019.
Juvéderm VOLUMA	Mid-Face Injection Via Cannula	Approved	FDA Approval announced September 3, 2019.

AGRX Agile Therapeutics Inc.

$1.24

-0.05  -3.88%

59.3 million

$73.5 million

214 thousand

542.7 thousand

0.39

$3.18

$1.28

$1.29

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Twirla	Contraceptive patch	PDUFA	CRLs issued 2013 and 2017. New PDUFA date November 16, 2019. Advisory Committee Meeting October 30, 2019.

AGTC Applied Genetic Technologies Corporation

$3.76

-0.04  -1.05%

18.2 million

$68.3 million

5.7 thousand

101.8 thousand

0.06

$0.77

$3.77

$3.80

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AAV Gene Therapy	CNGB3 Achromatopsia	Phase 1/2	Phase 1/2 interim dose-escalation data due 4Q 2019.
rAAV-hRS1	X-linked retinoschisis (XLRS)	Phase 1/2	Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
AAV-based gene therapy	X-linked Retinitis Pigmentosa (XLRP)	Phase 1/2	Phase 1/2 dose escalation data due 3Q 2019. Expansion data due 4Q 2019.

AIM Hemispherx BioPharma Inc.

$3.10

+1.44  +87.28%

2.4 million

$7.6 million

0.84

6.5 million

98.8 thousand

65.95

$1.42

$3.36

$1.66

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Ampligen	CFS	CRL	CRL February 4, 2013.
Ampligen, Intron A, celecoxib and pembrolizumab	Triple-Negative Breast Cancer	Phase 1	Phase 1 data due 2020.
Ampligen, Intron A, and celecoxib	Colorectal cancer	Phase 2	Phase 2 data due 2020.
Ampligen, cisplatin and pembrolizumab	Ovarian cancer	Phase 2	Phase 2 initiation of patient dosing announced June 12, 2019 with data due 2021.
Ampligen, Intron A	Prostate Cancer	Phase 2	Phase 2 trial to commence June 2019.

AIMT Aimmune Therapeutics Inc.

$22.89

+0.12  +0.51%

62.7 million

$1.4 billion

157.1 thousand

956 thousand

0.16

$7.00

$22.75

$22.77

09/19/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
AR101 ARTEMIS	Peanut Allergy	Phase 3	Phase 3 trial met primary endpoint - March 25, 2019.
AR101 RAMSES	Peanut Allergy	Phase 3	Phase 3 data released November 8, 2018 noted no serious adverse events
AR101	Peanut Allergy	PDUFA	PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019 voted in favor of supporting approval.
AR 201	Egg Allergy	Phase 2	Phase 2 initiation of enrolment announced August 21, 2019.
AR101 with adjunctive dupilumab	Peanut Allergy	Phase 2	Phase 2 trial initiation announced October 15, 2018.
AR101 POSEIDON	Peanut Allergy	Phase 3	Phase 3 data due 2020.

AKBA Akebia Therapeutics Inc.

$4.52

-0.09  -1.95%

118.9 million

$537.3 million

99.6 thousand

832.2 thousand

0.12

$1.03

$4.58

$4.61

09/19/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Vadadustat - TRILO2GY	Three-times-weekly dosing regimen for vadadustat	Phase 3	Phase 3 trial to be initiated in 2019.
Vadadustat - FO2RWARD	Renal anemia	Phase 2	Phase 2 trial data due 2019.
Auryxia	Hyperphosphatemia	Approved	Approved Sept 5, 2014.
Vadadustat - INNO2VATE	Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)	Phase 3	Phase 3 data due 2Q 2020.
Vadadustat - PRO2TECT	Non-dialysis patients with anemia related to CKD (NDD-CKD)	Phase 3	Phase 3 data due mid-2020.
Auryxia	Iron deficiency anemia in non-dialysis dependent CKD patients	Approved	sNDA FDA Approval announced November 7, 2017.

AKCA Akcea Therapeutics Inc.

$21.66

-0.28  -1.28%

93 million

$2 billion

36.3 thousand

180.3 thousand

0.2

$5.47

$21.97

$21.94

09/19/2019

Tap to view 9 drug drugs

Drug	Indication	Stage	News
AKCEA-ANGPTL3-LRx	Rare hyperlipidemias	Phase 2	Pilot study data due mid-2019.
AKCEA-ANGPTL3-LRx	Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus	Phase 2	Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx	Hyperlipoproteinemia and established cardiovascular disease	Phase 2b	Phase 2b data due 1H 2020.
AKCEA-APO(a)-LRx	Hyperlipoproteinemia(a) and established cardiovascular disease	Phase 2b	Phase 3 trial to be initiated 2H 2019.
Inotersen (IONIS-TTRRx)	NEURO-TTR - familial amyloid polyneuropathy (FAP).	Approved	FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH	Familial chylomicronemia syndrome (FCS)	CRL	CRL issued August 27, 2018.
Volanesorsen	Partial lipodystrophy rapidly	Phase 3	Phase 3 initiated November 2015
Volanesorsen	Familial partial lipodystrophy (FPL)	Phase 3	Phase 3 data met primary endpoint - August 6, 2019.
AKCEA-TTR-LRx	hATTR Amyloidosis	Phase 1/2	Phase 1 data presented at HFSA September 13, 2019.

AKRO Akero Therapeutics Inc.

$19.43

+0.43  +2.25%

28.6 million

$554.7 million

11.7 thousand

91.9 thousand

0.13

$3.50

$19.06

$19.00

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AKR-001	Nonalcoholic steatohepatitis (NASH)	Phase 2a	Phase 2a data due 1Q 2020.

AKTX Akari Therapeutics Plc

$1.88

-0.04  -1.99%

20.4 million

$38.4 million

95.9 thousand

1.3 million

0.07

-$26.88

$1.93

$1.92

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Coversin - CAPSTONE	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 3	Phase 3 staged readouts - no definitive timeline set by company. 2019?
Coversin	Atopic keratoconjunctivitis	Phase 1/2	Phase 1/2 Part B data due 4Q 2019.
Coversin	Bullous Pemphigoid	Phase 2	Phase 2 further data due at EADV Congress, October 10, 2019.
Coversin	Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)	Phase 2	Pivotal trial to be initiated 4Q 2019.

ALBO Albireo Pharma Inc.

$24.00

-0.91  -3.65%

12.7 million

$304.4 million

27.1 thousand

51 thousand

0.53

$2.59

$25.00

$24.91

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Odevixibat (A4250) - PEDFIC- 1	Progressive familial intrahepatic cholestasis (PFIC)	Phase 3	Phase 3 top-line data due mid-2020.
Elobixibat	Nonalcoholic steatohepatitis (NASH)	Phase 2	Phase 2 data due mid-2020.
Odevixibat (A4250)	Biliary atresia	Phase 3	Phase 3 trial planned for 2020.

ALDR Alder BioPharmaceuticals Inc.

$18.71

  +0.00%

83.6 million

$1.6 billion

1.6 million

2.1 million

0.75

$14.17

$18.75

$18.71

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Eptinezumab ALD403	Frequent episodic migraine	PDUFA	PDUFA date February 21, 2020.
ALD403	Chronic Migraine	Phase 2b	Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1	Frequent episodic migraine	Phase 3	Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised.
Eptinezumab	Acute migraine	Phase 3	Phase 3 trial to be initiated 2H 2019.

ALDX Aldeyra Therapeutics Inc.

$5.80

+0.05  +0.87%

27.6 million

$160 million

26.3 thousand

177.4 thousand

0.15

$2.38

$5.66

$5.75

09/19/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
ADX-102 - topical ocular reproxalap - RENEW	Dry eye syndrome	Phase 3	Phase 3 (Part 1) to be completed 4Q 2019.
Reproxalap (ADX-102)	Allergic conjunctivitis	Phase 3	Phase 3 data March 25, 2019 - primary endpoint met.
ADX-102 reproxalap	Noninfectious anterior uveitis	Phase 3	Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102)	Sjögren-Larsson Syndrome (SLS)	Phase 3	Phase 3 Part 1 section of trial completed.
ADX-1612 (ganetespib)	Post-transplant lymphoproliferative disorder	Phase 2	Phase 2 trial to be initiated 2H 2019.
ADX-2191	Proliferative vitreoretinopathy (PVR)	Phase 3	Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
ADX-2191	Proliferative vitreoretinopathy (PVR)	Phase 3	Phase 3 trial to be initiated 4Q 2019 with initial data due 2020.

ALEC Alector Inc.

$19.02

-0.21  -1.09%

68.8 million

$1.3 billion

93 thousand

307.9 thousand

0.3

$5.33

$19.24

$19.23

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AL001	Frontotemporal Dementia	Phase 1	Phase 2 trial initiation announced September 9, 2019.
AL002	Alzheimer’s disease	Phase 1	Phase 1 initiation of dosing announced May 6, 2019.
AL003	Alzheimer’s disease	Phase 1	Phase 1 trial initiation announced April 3, 2019.

ALIM Alimera Sciences Inc.

$0.45

+0.03  +6.61%

71 million

$32 million

148.4 thousand

268.7 thousand

0.55

-$0.94

$0.42

$0.42

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Iluvien	Diabetic macular edema	Approved	CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014

ALKS Alkermes plc

$21.73

+0.25  +1.16%

157.1 million

$3.4 billion

126.6 thousand

1.3 million

0.1

$3.13

$21.40

$21.48

09/19/2019

Tap to view 13 drug drugs

Drug	Indication	Stage	News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)	Schizophrenia	Approved	FDA approval announced July 2, 2018.
ALKS 3831 - ENLIGHTEN-Early	Schizophrenia - young adults	Phase 3	Phase 3 data due early 2020.
ALKS 3831 - ENLIGHTEN-2	Schizophrenia, bipolar	NDA Filing	Noted July 15, 2019 that NDA filing due 4Q 2019 will include Bipolar I indication
BYDUREON	Type 2 diabetes	Approved	CRL received March 15, 2010.
Aristada	Schizophrenia	Approved	Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098)	Multiple sclerosis (MS)	PDUFA	NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
ALKS 6428	Opioid dependence	Phase 3	Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461	Major depressive disorder	CRL	CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1	Schizophrenia	Phase 3	Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1	Solid tumors	Phase 1	Phase 1/2 data due 2H 2019.
Aristada and Invega Sustenna	Schizophrenia	Phase 3	Phase 3 data released April 9, 2019 - primary endpoint met.
ALKS 4230 + Keytruda - ARTISTRY-2	Solid tumors	Phase 1	Phase 1 initiation announced February 26, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -	Relapsing Remitting Multiple Sclerosis (RRMS)	Phase 3	Phase 3 top-line data met primary endpoint - July 30, 2019.

ALLK Allakos Inc.

$82.85

+1.49  +1.83%

48.4 million

$4 billion

86.8 thousand

759.6 thousand

0.11

$26.39

$81.36

$81.36

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AK002	Severe Allergic Conjunctivitis	Phase 1	Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms
AK002	Indolent Systemic Mastocytosis	Phase 1	Phase 1 data released February 19, 2019.
AK002	Chronic Urticaria	Phase 2	Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002	Eosinophilic Gastritis	Phase 2	Phase 2 top-line data met primary and secondary endpoints - August 5, 2019. Extension data due 1H 2020. Phase 3 trial to commence 1Q 2020.

ALLO Allogene Therapeutics Inc.

$33.18

+0.44  +1.34%

121.7 million

$4 billion

39.3 thousand

321 thousand

0.12

$6.16

$32.74

$32.74

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
UCART19 (PALL)	Acute lymphoblastic leukemia (ALL)	Phase 1	Phase 1 update at ASH December 3, 2018 noted 86% CR/CRi.
UCART19 - CALM	Refractory B-cell Acute Lymphoblastic Leukaemia	Phase 1	Phase 1 update 2019.
ALLO-715	Multiple myeloma	Phase 1/2	Phase 1/2 trial to be initiated in 2H 2019.
ALLO-501 - ALPHA	Non-Hodgkin lymphoma (NHL)	Phase 1	Phase 1 initial data due 1H 2020.

ALNA Allena Pharmaceuticals Inc.

$4.15

-0.02  -0.48%

23.5 million

$97.4 million

43.6 thousand

53.3 thousand

0.82

$2.58

$4.24

$4.17

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Reloxaliase ALLN-177 (URIROX-1)	Enteric Hyperoxaluria	Phase 3	Phase 3 top-line data due 4Q 2019.
Reloxaliase ALLN-177 (Study 206)	Primary hyperoxaluria	Phase 2	Phase 2 top-line data due 2H 2019.
Reloxaliase ALLN-177 (URIROX-2)	Enteric Hyperoxaluria	Phase 3	Phase 3 data due 2H 2021.

ALNY Alnylam Pharmaceuticals Inc.

$85.20

-0.29  -0.34%

111.2 million

$9.5 billion

174 thousand

740.7 thousand

0.23

$5.39

$85.84

$85.49

09/19/2019

Tap to view 17 drug drugs

Drug	Indication	Stage	News
Fitusiran	Hemophilia A and B	Phase 2	Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Givosiran	Acute hepatic porphyrias	PDUFA priority review	PDUFA date under priority review February 4, 2020.
Inclisiran - ORION-9	Hypercholesterolemia	Phase 3	Phase 3 data due second half of 3Q 2019.
ALN-HBV02 (VIR-2218))	Chronic hepatitis B virus (HBV)	Phase 1/2	Phase 1/2 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A	Primary Hyperoxaluria Type 1 (PH1)	Phase 3	Phase 3 data due late-2019.
Patisiran	Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Approved	FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran)	IgA nephropathy	Phase 2	Phase 2 trial to be initiated.
Fitusiran (ATLAS)	Hemophilia	Phase 3	Phase 3 first read-out expected 2H 2019
ALN-TTRsc02 - HELIOS-A	ATTR amyloidosis	Phase 3	Phase 3 trial enrolling - noted December 6, 2018.
Inclisiran - ORION-10	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 data due second half of 3Q 2019.
Inclisiran - ORION 11	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
ALN-AAT02	alpha-1 anti-trypsin deficiency-associated liver disease	Phase 1/2	Phase 1/2 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-B	Primary Hyperoxaluria Type 1	Phase 3	Phase 3 top-line data due mid-2020.
Patisiran APOLLO-B	Wild-type ATTR amyloidosis patients with cardiomyopathy	Phase 3	Phase 3 trial initiation announced September 16, 2019.
Lumasiran (ALN-GO1) ILLUMINATE-C	Impaired renal function	Phase 3	Phase 3 trial to be initiated 2H 2019.
ALN-AGT	Hypertension	Phase 1	Phase 1 dosing has commenced - noted May 31, 2019. Initial data due late-2019.
ALN-TTRsc02 (vutrisiran) - HELIOS-B	ATTR amyloidosis with cardiomyopathy	Phase 3	Phase 3 trial to be initiated 2H 2019.

ALPN Alpine Immune Sciences Inc.

$4.33

-0.02  -0.46%

18.6 million

$80.5 million

7.4 thousand

13.9 thousand

0.53

$1.77

$4.20

$4.35

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
N91115	Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein	Phase 2	Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101	Healthy volunteers	Phase 1	Phase 1 safety trial critical portions to be completed by end of 2019.
ALPN-202	Advanced Malignancies	Phase 1	Phase 1 trial to be initiated 1Q 2020.

ALRN Aileron Therapeutics Inc.

$0.94

-0.01  -0.59%

27.8 million

$26.3 million

67.4 thousand

367.6 thousand

0.18

$0.87

$0.95

$0.95

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ALRN-6924	Peripheral T-cell lymphoma (PTCL)	Phase 2a	Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C)	Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)	Phase 1b	Phase 1/1b data due 4Q 2019.
ALRN-6924 and IBRANCE (palbociclib)	Solid tumors	Phase 2a	Phase 2a preliminary data due at ESMO Sept 28, 2019 with final data due 2H 2020.
ALRN-6924 and Paclitaxel	Breast cancer	Phase 1	Phase 1 has been initiated.
ALRN-6924	Small Cell Lung Cancer (SCLC)	Phase 1/2	Phase 1b/2 trial to commence September 2019 with data due 2Q 2020.

ALT Altimmune Inc.

$2.12

+0.02  +0.93%

15.3 million

$32.5 million

32.3 thousand

188.3 thousand

0.17

$0.58

$2.10

$2.10

09/19/2019

Tap to view 4 drug drugs

Drug	Indication	Stage	News
HepTCell	Hepatitis B	Phase 1	Phase 2 trial planned for 2020.
NasoVAX	Flu vaccine	Phase 2	Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD	Anthrax	Phase 1	Phase 1b trial to be initiated in 2019.
ALT-801	Non-alcoholic steatohepatitis (NASH)	Phase 1	IND to be filed in 2020 with Phase 1 data due 2021.

ALXN Alexion Pharmaceuticals Inc.

$105.37

+2.39  +2.32%

224.2 million

$23.6 billion

579.4 thousand

2.6 million

0.23

$2.33

$103.65

$102.98

09/19/2019

Tap to view 12 drug drugs

Drug	Indication	Stage	News
CAEL‐101	AL amyloidosis	Phase 2/3	Phase 2b/3 trial to be initiated in 2020 with data due in 2021.
Eculizumab	Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Approved	FDA Approval announced June 27, 2019.
ALXN1210	atypical Hemolytic Uremic Syndrome (aHUS)	PDUFA priority review	PDUFA data under priority review October 19, 2019.
ULTOMIRIS (ravulizumab-cwvz)	Paroxysmal nocturnal hemoglobinuria (PNH)	Approved	FDA approval announced December 21, 2018.
Eculizumab	Refractory generalized myasthenia gravis (gMG)	Approved	Approval announced October 23, 2017.
ALXN1840 (WTX101)	Wilson disease	Phase 3	Phase 3 enrolment to be completed early 2020.
ULTOMIRIS (ravulizumab-cwvz)	Generalized myasthenia gravis (gMG)	Phase 3	Phase 3 trial initiated 1Q 2019.
ALXN1830	Warm autoimmune hemolytic anemia (WAIHA)	Phase 1/2	Phase 1b/2a data due 2H 2019. Phase 2/3 trial to be initiated early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous	Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3	Phase 3 PK data due early 2020.
ULTOMIRIS	Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)	Phase 3	Phase 3 trial to commence 1H 2020.
Eculizumab	Generalized myasthenia gravis (gMG) - children	Phase 3	Phase 3 trial to commence by the end of 2019.
Eculizumab	Neuromyelitis Optica Spectrum Disorder (NMOSD) - children	Phase 3	Phase 3 trial to commence by the end of 2019.

AMAG AMAG Pharmaceuticals Inc.

$12.32

+0.26  +2.16%

33.9 million

$417.7 million

204.3 thousand

1.3 million

0.16

$0.84

$12.30

$12.06

09/19/2019

Tap to view 6 drug drugs

Drug	Indication	Stage	News
AMAG-423 / Digoxin immune fab (DIF)	Severe preeclampsia in pregnant women	Phase 2/3	Phase 2/3 top-line data due 1H 2020.
Vyleesi (Bremelanotide)	Female sexual dysfunction (FSD)	Approved	FDA approval announced June 21, 2019.
Feraheme	Adults with iron deficiency anemia (IDA)	Approved	Approval for sNDA filing announced February 5, 2018.
Makena - auto injector	Reduce the risk of preterm birth in women with a singleton pregnancy	Approved	Approval announced February 14, 2018.
Makena	Preterm birth	Phase 3	Phase 3b trial did not meet co-primary endpoints. Advisory Committee planned for 4Q 2019. Data to be published 2H 2019.
Ciraparantag	Anticoagulated reversal agent / Healthy volunteers	Phase 2	Phase 3a trial to be initiated 4Q 2019.

AMGN Amgen Inc.

$195.78

+0.74  +0.38%

599.7 million

$117.4 billion

278.6 thousand

3.3 million

0.09

$10.88

$195.72

$195.04

09/19/2019

Tap to view 28 drug drugs

Drug	Indication	Stage	News
Tezepelumab - NAVIGATOR	Asthma	Phase 3	Phase 3 data due 2H 2020.
Prolia (denosumab)	Glucocorticoid-induced osteoporosis (GIOP)	Approved	Approval announced May 21, 2018.
KYPROLIS (ASPIRE)	Relapsed Multiple Myeloma	Approved	sNDA approval announced June 11, 2018.
Vectibix (Panitumumab)	Wild-Type RAS Metastatic Colorectal Cancer	Approved	sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	PDUFA	Approved September 14, 2017.
Corlanor	Chronic Heart Failure	Approved	Approved April 15, 2015.
Erenumab	Migraine	Approved	Approval announced May 17, 2018.
CNP 520	Alzheimer’s Disease	Phase 3	Phase 3 ongoing. Expected completion 2024.
Repatha	Cardiovascular disease	Approved	Approval announced December 1, 2017.
XGEVA	Multiple Myeloma	Approved	sBLA approval announced January 5, 2017.
KYPROLIS (ARROW)	Multiple Myeloma	Approved	FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR)	Relapsed Multiple Myeloma	Approved	sNDA approved January 17, 2018.
BLINCYTO	Ph+ R/R ALL	Approved	PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	Phase 3	Phase 3 data released January 24, 2019 - primary endpoint met in rheumatoid arthritis trial. Non-Hodgkin’s lymphoma data also met primary endpoint showing clinical equivalence - August 22, 2019.
ABP 980 (Kanjinti; trastuzumab-anns)	Herceptin biosimilar	CRL	FDA approval announced June 13, 2019.
ABP 710	REMICADE biosimilar - rheumatoid arthritis	PDUFA	BsUFA date December 14, 2019.
Parsabiv	Secondary hyperparathyroidism (SHPT)	Approved	Approved February 7, 2017.
EVENITY (Romosozumab)	Osteoporosis	Approved	FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF	Acute heart failure	Phase 3	Phase 3 interim analysis 1H 2020.
Omecamtiv mecarbil METEORIC-HF	Acute heart failure	Phase 3	Second Phase 3 trial initiation announced February 21, 2019.
AMG 420	Relapsed. Refractory (R/R) Multiple Myeloma (MM)	Phase 1	Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 330	Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	Phase 1	Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
Nplate (Romiplostim)	Immune Thrombocytopenia (Pediatric)	Approved	FDA approval announced December 14, 2018.
Nplate (Romiplostim)	Immune thrombocytopenia (ITP)	PDUFA	sNDA filing announced December 19, 2018. Estimated PDUFA date October 18, 2019.
KYPROLIS (CANDOR)	Multiple Myeloma	Phase 3	Phase 3 data due 2019.
AMG 594	Healthy volunteers	Phase 1	Phase 1 trial initiation announced February 20, 2019.
AMG 510	Solid tumors	Phase 1	Phase 1 presentation at ESMO September 28, 2019, 4:52pm CEST.
CNP520	Alzheimer’s Disease	Phase 2/3	Phase 2/3 trial discontinued due to lack of efficacy.

AMPE Ampio Pharmaceuticals Inc.

$0.48

-0.01  -1.63%

142.2 million

$68.5 million

16.35

65.6 thousand

737.2 thousand

0.09

$6.03

$0.49

$0.49

09/19/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Ampion	Osteoarthritis of the Knee	Phase 3	As of July 24, 2019 enrolment has reached approximately 30%.
Optina	Diabetic Macula Edema	Phase 2b	Phase 2b data released May 2015 did not meet endpoints

AMPH Amphastar Pharmaceuticals Inc.

$21.32

+0.1  +0.47%

47.2 million

$1 billion

28.4 thousand

210.3 thousand

0.14

$2.60

$21.23

$21.22

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Albuterol DPI	Asthma	Phase 2b
Naloxone Intranasal	Opioid overdose	CRL	CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol)	Asthma	CRL	CRL issued December 27, 2016.

AMRN Amarin Corporation plc

$16.88

-0.05  -0.30%

357.2 million

$6 billion

1.6 million

8.5 million

0.19

$46.89

$17.03

$16.93

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Vascepa	High Triglycerides With Mixed Dyslipidemia	PDUFA priority review	Advisory Committee meeting November 14, 2019. PDUFA date under priority review September 28, 2019 extended to December 28, 2019.

AMRX Amneal Pharmaceuticals Inc. Class A

$3.17

-0.09  -2.61%

299.1 million

$949.6 million

3.89

162.2 thousand

2.5 million

0.07

$2.06

$3.28

$3.26

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
IPX203	Parkinson's disease	Phase 3	Phase 3 data due 1H 2020.

ANAB AnaptysBio Inc.

$42.24

-0.42  -0.98%

27 million

$1.1 billion

26.6 thousand

273.4 thousand

0.1

$2.55

$42.80

$42.66

09/19/2019

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ANB020 - etokimab	Moderate-to-severe adult atopic dermatitis	Phase 2b	Phase 2b data due 4Q 2019.
ANB020 - etokimab	Severe adult eosinophilic asthma	Phase 2a	Phase 2b trial to be initiated 4Q 2019.
ANB019	Palmo-plantar pustular psoriasis	Phase 2	Phase 2 data due 1H 2020.
ANB019	Generalized pustular psoriasis	Phase 2	Phase 2 data due mid-2019.
ANB020 - etokimab	Nasal polyps	Phase 2	Phase 2 data due 4Q 2019.

ANCN Anchiano Therapeutics Ltd.

$2.42

+0.09  +3.70%

7.4 million

$17.9 million

5.2 thousand

37.4 thousand

0.14

$0.72

$2.39

$2.33

09/19/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Inodiftagene - Codex	Non-muscle invasive bladder cancer (NMIBC)	Phase 2	Phase 2 interim analysis 4Q 2019.
Inodiftagene with BCG - Leo	Non-muscle invasive bladder cancer (NMIBC)	Phase 3	Phase 3 planned for 4Q 2019 or 1Q 2020.

ANIK Anika Therapeutics Inc.

$54.25

-0.07  -0.13%

13.8 million

$747.7 million

36.1 thousand

205.4 thousand

0.18

$2.98

$54.35

$54.32

09/19/2019

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Cingal	Osteoarthritis	Phase 3	Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated 1H 2020.
Monovisc	Osteoarthritis	Approved	Approved Feb 2014
HYALOFAST	Cartilage defects of the knee	Phase 3	Phase 3 enrollment to be completed by the end of 2018.

ANIX Anixa Biosciences Inc.

$4.35

+0.1  +2.35%

20.2 million

$87.9 million

8.8 thousand

86.3 thousand

0.1

$13.18

$4.25

$4.25

09/19/2019

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Breast cancer vaccine		Phase 1

APLS Apellis Pharmaceuticals Inc.

$26.60

+0.35  +1.33%

63.7 million

$1.7 billion

167.7 thousand

456.3 thousand

0.37

$10.64

$26.16

$26.25

09/19/2019

Tap to view 7 drug drugs

Drug	Indication	Stage	News
APL-2 subcutaneous	Cold agglutinin disease (CAD)	Phase 2	Phase 3 trial to be initiated in early 2020.
APL-2 PHAROAH	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 1b	Phase 1b trial ongoing.
APL-2 OAKS	Geographic atrophy (GA) associated with age-related macular degeneration (AMD)	Phase 3	Phase 3 enrolment to be completed 1Q 2020.
APL-2 subcutaneous PEGASUS	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 3	Phase 3 data due December 2019.
APL-2 PADDOCK	Paroxysmal Nocturnal Hemoglobinuria	Phase 1	Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
APL-2 subcutaneous	Complement-dependent Nephropathies (CDN)	Phase 2	Phase 2 data due at ASN meeting November 05 - 10, 2019.
APL-2 PRINCE	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 3	Phase 3 commencement of dosing announced September 3, 2019.

APLT Applied Therapeutics Inc.

$9.71

-0.17  -1.69%

17.1 million

$165.6 million

6.6 thousand

12.4 thousand

0.53

$4.13

$10.00

$9.88

09/19/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
AT-001	Diabetic cardiomyopathy (DbCM)	Phase 3	Phase 3 trial initiation announced September 4, 2019.
AT-007	Galactosemia	Phase 1	Phase 1 additional data due fall of 2019.

APTO Aptose Biosciences Inc.

$2.39

+0.04  +1.70%

55.4 million

$132.5 million

18.3 thousand

297.2 thousand

0.06

$3.92

$2.38

$2.35

09/19/2019

Tap to view 2 drug drugs

Drug	Indication	Stage	News
APTO-253	Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)	Phase 1b	Phase 1b data due later in 2019.
CG-806	Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)	Phase 1	Phase 1 safety/response data due late-2019.

APTX Aptinyx Inc.

$3.95

-0.05  -1.25%

33.7 million

$133 million